61 results about "Anti viral immunity" patented technology

The present invention relates to compositions and methods for enhancing an immune response, for example to a vaccine, by combining the administration of oxygen (O2 gas), an adenosine pathway antagonist and / or an HIF-1α antagonist, and / or inhibitors of enzymes that produce or generate adenosine with the administration of the vaccine to the patient.The present invention also relates to methods of inducing or enhancing immune responses, methods of treating subjects having a tumor, methods of ablating or killing tumor cells and methods of disrupting the blood supply to a tumor, comprising administering oxygen alone or in combination with therapeutic agents that prevent inhibition of anti-tumor T cells. Tumor defense-resistant immune cells, anti-viral immune cells, and methods of their production are also disclosed.

The invention provides a fusion protein comprising the Plasmodium merozoite surface protein-1 (MSP1) and the Plasmodium apical membrane antigen 1 (AMA-1), the encoding DNA sequence, the vector containing the sequence, the host cell containing the vector, and the genetic engineering method for preparing the fusion protein and the usage for producing anti-malarial vaccine. The AMA-1 / MSP1 fusion protein of the present invention has excellent immunogenicity and can cause an effective immune response against Plasmodium in individuals.

Virus vectors, virus particles, and methods and uses of screening for, detecting, analyzing and determining amounts of virus antibody, or neutralizing antibody activity of samples are provided. Such virus vectors, virus particles, and methods and uses are applicable to a broad range of virus types, such as lentiviruses, adenovirus, and adeno-associated virus (AAV) serotypes. Methods and uses include virus antibody screening, such as anti-virus immunoglobulins screened for, detected, analyzed and amounts determined

A sensor chip for detecting an immune response against an influenza virus, the sensor chip including a substrate having a surface and a plurality of hemagglutinin polypeptides bound to discrete locations on the surface of the substrate, each hemagglutinin polypeptide having a hemagglutinin epitope. Detection devices containing the sensor chip and methods of detecting influenza immune responses are also described herein.

The invention discloses an antisense oligonucleotide targeting a COVID-19 new coronavirus, a chimeric molecule and application thereof. Antisense nucleic acids targeting S protein and E protein are respectively designed and synthesized according to RNA (Ribonucleic Acid) sequences of spike protein and envelope protein of COVID-19 new coronavirus, and part of the antisense nucleic acids are further conjugated with a functional group 2'-5' adenine of targeting ribonuclease L to obtain the chimeric molecule. The antisense oligonucleoside nucleic acid and the antisense nucleic acid chimeric molecule (NATAC molecule) thereof provided by the invention can obviously reduce the expression level of target RNA (Ribonucleic Acid), meanwhile, obviously activate the expression of ribonuclease L, beta-interferon and interleukin 6 in cells, show obvious drug effect advantages and can effectively activate potential antiviral immunity in the cells. Therefore, the antisense oligonucleotide or the chimeric molecule provided by the invention can be used as a nucleic acid drug for preventing or treating COVID-19 new coronavirus infection.

The HIV-specific cytotoxic T lymphocyte (CTL) response is a critical component in controlling HIV replication and is an important part of the ultimate failure to eradicate the virus. Disclosed herein are methods for genetically enhancing the HIV-specific CTL response to allow long-term viral suppression or viral clearance. Human hematopoietic stem cells (HSCs) were genetically modified such that they differentiate into mature CTLs that will kill HIV infected cells. As disclosed herein, the functional effector cells are not human leukocyte antigen (HLA)-restricted. As disclosed herein, stem cells are transduced with non-HLA restricted chimeric antigen receptors (CARs) that allow the recognition of HIV or HIV-infected cells when expressed by a CTL. These CARs are hybrid molecules that contain an extracellular HIV recognition domain and an intracellular TCR-zeta signaling domain. The CTL response may be enhanced through the targeting of T cell inhibitory receptors. The methods and compositions disclosed herein may be used to engineer antiviral immunity and HIV-specific CTL responses in vivo. Also disclosed herein are methods and compositions for the treatment of chronic viral infections such as HIV.

The invention relates to a method for preparing a gene therapy medicine for novel corona virus 2019. The method comprises the following steps: according to an nCoV2019 (novel corona virus 2019) genome, screening an siRNA (small interference ribonucleic acid) sequence with an RNA interference effect, and performing synthesis by using a nucleic acid synthesis method; and preparing synthesized nCoV2019siRNA into lipid nanoparticles LHNPs, and compounding LHNPs or nCoV2019siRNA with a spray, so as to obtain a gene therapy product with inhalation administration. When reaching target cells, siRNA isdegraded since an siRNA antisense strand which is generated under the action of inherent and stress boosted helicase and endonuclease / exonuclease is combined with homologous RNA and / or mRNA (messenger ribonucleic acid). In addition, type-I interferon, IL-6, TNFa (tumor necrosis factor a) and the like can be generated under stimulation of double-strand siRNA and cellular immunity can be mediated,it is known that type-I interferon has antiviral immunity, IL-6 is capable of inducing hyperplasia of immune globulin and T cells, and the TNFa is capable of promoting infection resistance of neutrophile granulocyte, inducing apoptosis of virus infected cells and thus inhibiting virus hyperplasia, so that in addition to virus prevention of RNA interference, antibacterial antiviral immunity of cellfactors, immune cells and immune globulin can be also triggered, and in addition, the medicine can be efficiently and rapidly synthesized, and is easy in short-term application to treatment or prevention.

A diagnostic method for the prediction of the development and control of the effectiveness of the treatment of cardiovascular diseases, in which patient tissue samples are taken, microassay are prepared, specific antiviral immunoglobulins are processed, the number of cells infected by two or more viruses before the beginning of treatment are determined, and the dynamic of the change in the number of infected cells and their interrelationships are established: when the number of cells infected by cytomegalovirus and any other viruses decreases by more than 50±10% in patients without symptoms of cardiovascular pathology, a diagnostic conclusion is high danger of the development of atherosclerosis; if the number of cells infected by cytomegalovirus and any other viruses exceeds 50±10% in patients with demonstrated clinical signs of cardiovascular system pathology, a diagnostic conclusion is drawn of the danger of the development of complications such as arrhythmia, thrombolytic embolism.

Viral-based vectors are genetically engineered to express inhibitors of the anti-viral immune system (e.g. inhibitors of the type I interferon response) in order to enhance transgene expression. The transgenes may encode antigens or other therapeutic agents.

A sensor chip for detecting an immune response against a virus, the sensor chip including a substrate having a surface and a plurality of virus-like particles or capsid fragments bound to discrete locations on the surface of the substrate. Detection devices containing the sensor chip and methods of detecting anti-viral immune responses are also described herein.